Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2
About this episode
The episode discusses the potential role of GLP-1 receptor agonists in treating inflammatory arthritides based on early data.
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.
People in this episode
Hosts: Jack Arnold, Rihards Buss
Topics covered
- GLP-1 receptor agonists
- rheumatoid arthritis
- psoriatic arthritis
- lupus
- disease modification
- inflammatory arthritides
Mentioned in this episode
Organizations: University of Leeds, Freeman Hospital
Products: GLP-1 receptor agonists
Places: Newcastle
More episodes of HCPLive Podcasts
- Joint Ventures: EULAR 2026 Congress Preview
- Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus
- Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier
- Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1
- Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms
- Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS
Explore listener stats, chart rankings, contacts and more on the HCPLive Podcasts podcast page.